TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18321743

Group type: EXPERIMENTAL
Intervention: MK-0873 (2.5mg for 6 days) + Theophylline (250mg on day 5)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Theophylline (250mg on day 1)
Number of subjects: 8
Study: 16426959

Group type: EXPERIMENTAL
Intervention: Micronutrient-enriched beverage for 14 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14713138

Group type: EXPERIMENTAL
Intervention: Contingency management intervention with vouchers redeemable for tokens (values from 0.00 to 100.00 dollars)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Variable rate of reinforcement (as in Study 1)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Fixed value reinforcer of 3.25 dollars
Number of subjects: 102

Group type: COMPARATOR
Intervention: Variable and fixed reinforcement groups
Number of subjects: 102
Study: 11016399

Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide (59 mg Al/ml), 10 ml three times daily for 6 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Referent group (no aluminum exposure)
Number of subjects: 18
Study: 9184389

Group type: EXPERIMENTAL
Intervention: Moderate intensity oral anticoagulant treatment (target INR = 3)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Moderate-high intensity oral anticoagulant treatment (target INR = 4)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Both groups (target INR = 3 and target INR = 4)
Number of subjects: 205
Study: 1347670

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trifluoperazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 7033947

Group type: EXPERIMENTAL
Intervention: bendrofluazide 5 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: indapamide 2.5 mg
Number of subjects: 17
Study: 30293931

Group type: EXPERIMENTAL
Intervention: Oral zonisamide (4-25 mg/kg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intramuscular adrenocorticotropic hormone (30-60 IU)
Number of subjects: 30
Study: 28130990

Group type: EXPERIMENTAL
Intervention: Naltrexone treatment with different drug counseling models
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Cluster analysis of psychiatric symptoms
Number of subjects: 328
Study: 25892382

Group type: EXPERIMENTAL
Intervention: Acute bout of submaximal cycling exercise
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no exercise, reaction time tests after 30 min)
Number of subjects: 29
Study: 23669386

Group type: EXPERIMENTAL
Intervention: 20, 100, or 200 mg of oral oseltamivir BID for 5 days
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 200 mg oseltamivir once daily for 5 days
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 75 or 150 mg of oral oseltamivir BID for 5 days
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 140
Study: 22133339

Group type: EXPERIMENTAL
Intervention: Insight training course using the e-learning tool DART
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 18985374

Group type: EXPERIMENTAL
Intervention: Prednisolone (PRED, 60 mg/day for 1 week)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 17891560

Group type: EXPERIMENTAL
Intervention: ULEM therapy and conventional physical therapy (PT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: PT only
Number of subjects: 44
Study: 16898618

Group type: EXPERIMENTAL
Intervention: Alosetron (5-HT3 receptor antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilansetron (5-HT3 antagonist)
Number of subjects: 0
Study: 12800788

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug treatments
Number of subjects: 0
Study: 10052839

Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g, single dose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7595029

Group type: EXPERIMENTAL
Intervention: HBOC‐201 (up to 45 gm or 350 ml)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control solution (Ringer's lactate)
Number of subjects: 24
Study: 2099071

Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine (3 tablets, 300,000 binding units of the toxoid and 10,000 units of O‐antigens)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine
Number of subjects: 276

Group type: COMPARATOR
Intervention: Parenteral vaccines
Number of subjects: 276
Study: 7010203

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control
Number of subjects: 59
Study: 31594037

Group type: EXPERIMENTAL
Intervention: upadacitinib (3, 6, 12, 24 mg b.i.d. or 24 mg q.d.)
Number of subjects: 216

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 216
Study: 28936712

Group type: EXPERIMENTAL
Intervention: Early goal-directed nutrition (EGDN)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Standard nutritional care
Number of subjects: 199
Study: 25947301

Group type: EXPERIMENTAL
Intervention: Complex intervention (A) - educational outreach visit with GPs and guideline by mail
Number of subjects: 3443

Group type: COMPARATOR
Intervention: Simple intervention (B) - guideline by mail only
Number of subjects: 3443

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 3443

Group type: EXPERIMENTAL
Intervention: Complex intervention (A)
Number of subjects: 3443

Group type: COMPARATOR
Intervention: Simple intervention (B)
Number of subjects: 3443
Study: 24135599

Group type: EXPERIMENTAL
Intervention: Dehydrated Enterococcus faecium at 1 × 10(9) cfu/kg of feed
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Colistine sulfate at 10 mg/kg of feed
Number of subjects: 288

Group type: COMPARATOR
Intervention: Positive control (challenged with E. coli K88)
Number of subjects: 288
Study: 21711517

Group type: EXPERIMENTAL
Intervention: PS-DHA (300 mg PS/day) for 15 weeks
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: PS-DHA (100 mg PS/day) for 30 weeks (open-label extension)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo for 15 weeks
Number of subjects: 157
Study: 18435185

Group type: EXPERIMENTAL
Intervention: 38% hydrogen peroxide (HP) (Opalescence Xtra Boost)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 35% carbamide peroxide (CP) (Rembrandt Quik Start)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (CTRL) - baseline measurements
Number of subjects: 18
Study: 16608782

Group type: EXPERIMENTAL
Intervention: Local collagen-gentamicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous prophylaxis alone
Number of subjects: 0
Study: 12876389

Group type: EXPERIMENTAL
Intervention: Loss of heterozygosity involving 1p
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Loss of heterozygosity involving 19q
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Combination of 1p and 19q loss
Number of subjects: 121

Group type: COMPARATOR
Intervention: Chemotherapeutic regimens
Number of subjects: 121

Group type: COMPARATOR
Intervention: Subgroups stratified by age, tumor location, or tumor histology
Number of subjects: 121
Study: 10966240

Group type: EXPERIMENTAL
Intervention: E5531 (100, 250, 500, or 1000 microg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: E5531 (250, 500, or 1000 microg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: E5531 (any dose)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 8999618

Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms twice daily
Number of subjects: 304

Group type: COMPARATOR
Intervention: Salbutamol 400 micrograms four times daily
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 1296467

Group type: EXPERIMENTAL
Intervention: Soluprick SQ (ALK)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Alphatest (DHS)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Phazet (PHA)
Number of subjects: 200
Study: 6219578

Group type: EXPERIMENTAL
Intervention: Oral phosphate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mithramycin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: EHDP (ethane‐1‐hydroxy‐1, 1‐diphosphonate)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: APD (3‐amino‐1‐hydroxypropane‐1, 1‐diphosphonate)
Number of subjects: 15
Study: 30538099

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 1157
Study: 28858925

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) at subpurpuric settings
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control side (no treatment)
Number of subjects: 20
Study: 26827294

Group type: EXPERIMENTAL
Intervention: Intranasal delivery of oxytocin (OT)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Follow-up experiment with perceived human-like characteristics of inanimate objects
Number of subjects: 51
Study: 24662784

Group type: EXPERIMENTAL
Intervention: Anorexia Nervosa (AN) patients
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: AN patients
Number of subjects: 72
Study: 23139608

Group type: EXPERIMENTAL
Intervention: Symbiotic sachet Flortec(©) (Lactobacillus paracasei B21060) once daily plus high-fibre diet for 6 mo
Number of subjects: 45

Group type: COMPARATOR
Intervention: High-fibre diet alone for 6 mo
Number of subjects: 45
Study: 20879853

Group type: EXPERIMENTAL
Intervention: Antifungal treatment
Number of subjects: 119
Study: 17611607

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 578
Study: 15077082

Group type: EXPERIMENTAL
Intervention: Quinapril (10-20 mg per day)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 253
Study: 11730494

Group type: EXPERIMENTAL
Intervention: Uterine wipe
Number of subjects: 1230

Group type: COMPARATOR
Intervention: No wipe
Number of subjects: 1230
Study: 9389973

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) treatment for 12 months
Number of subjects: 24
Study: 7956625

Group type: EXPERIMENTAL
Intervention: Diabetic group (type I diabetes)
Number of subjects: 13
Study: 2883987

Group type: EXPERIMENTAL
Intervention: atenolol (50 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: pindolol (5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: epanolol (200 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study: 31941544

Group type: EXPERIMENTAL
Intervention: Disease activity‐guided treat‐to‐target strategy with tapering attempt
Number of subjects: 95

Group type: COMPARATOR
Intervention: Disease activity‐guided treat‐to‐target strategy without tapering attempt
Number of subjects: 95
Study: 28609578

Group type: EXPERIMENTAL
Intervention: Loss of a fellow service member (FSM)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Other bereaved individuals (not FSM)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Bereaved individuals
Number of subjects: 204
Study: 26706911

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (6 to 8 sessions)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Direct outreach to aging services providers
Number of subjects: 104
Study: 25708026

Group type: EXPERIMENTAL
Intervention: Piriformis fossa entry nailing
Number of subjects: 12

Group type: COMPARATOR
Intervention: Trochanteric entry nailing
Number of subjects: 12
Study: 23175674

Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study: 19711099

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg/day in 6-week cycles (Schedule 4/2)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Sorafenib 800 mg/day
Number of subjects: 292

Group type: COMPARATOR
Intervention: IFN-alfa 9 MU t.i.w.
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 18791486

Group type: EXPERIMENTAL
Intervention: Raloxifene plus ossein-hydroxyapatite compound (RLX + OHC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Raloxifene plus calcium carbonate (RLX + CC)
Number of subjects: 90
Study: 16773412

Group type: EXPERIMENTAL
Intervention: Urinary NGAL levels <200 ng/ml
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Urinary NGAL levels >=200 ng/ml
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Dialysis requirement
Number of subjects: 34
Study: 14672296

Group type: EXPERIMENTAL
Intervention: Meat supplement
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Milk supplement
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Energy supplement
Number of subjects: 544

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 544
Study: 10597759

Group type: EXPERIMENTAL
Intervention: Self-reported blood pressure (SBP, DBP) and heart rate (HR) measurements recorded by subjects using a digital BP monitor for 1 week.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Self-reported SBP in uncontrolled hypertension group.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Self-reported DBP in uncontrolled hypertension group.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Self-reported HR in cases where stored HR exceeded 100 beats/min.
Number of subjects: 30
Study: 8583618

Group type: EXPERIMENTAL
Intervention: 300 mg allopurinol daily
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 600 mg allopurinol daily
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 1957753

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg, alternate day)
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study: 7083769

Group type: EXPERIMENTAL
Intervention: Propranolol (oral and intravenous)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Propranolol absorption in untreated coeliac patients
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Propranolol absorption overall
Number of subjects: 13
Study: 30094545

Group type: COMPARATOR
Intervention: Zoledronic acid (ZA) alone
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) plus radiopharmaceuticals (Sr-89 or Sm-153)
Number of subjects: 261
Study: 26332193

Group type: EXPERIMENTAL
Intervention: Bivalirudin alone
Number of subjects: 13819

Group type: COMPARATOR
Intervention: Heparin alone, Bivalirudin alone, Heparin plus GPI, Bivalirudin plus GPI
Number of subjects: 13819

Group type: COMPARATOR
Intervention: Medical treatment phase
Number of subjects: 13819
Study: 25179366

Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment (IAT) including thrombolysis with alteplase or urokinase, mechanical treatment, or both.
Number of subjects: 500

Group type: COMPARATOR
Intervention: No intra-arterial treatment (no IAT).
Number of subjects: 500
Study: 22103774

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Interpersonal therapy
Number of subjects: 80
Study: 20473736

Group type: EXPERIMENTAL
Intervention: Xuezhikang Capsule
Number of subjects: 84

Group type: COMPARATOR
Intervention: Polyene phosphatidylcholine capsule
Number of subjects: 84
Study: 18322252

Group type: EXPERIMENTAL
Intervention: Bortezomib plus melphalan and prednisone (VMP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Melphalan plus prednisone (historical control)
Number of subjects: 60
Study: 16011059

Group type: EXPERIMENTAL
Intervention: Postoperative loco-regional radiation therapy
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control group (no radiation therapy)
Number of subjects: 258
Study: 12459659

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 20
Study: 10398981

Group type: EXPERIMENTAL
Intervention: 0.05 mmol/kg Gd-BOPTA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg Gd-BOPTA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GRE images
Number of subjects: 50
Study: 7593899

Group type: EXPERIMENTAL
Intervention: morphine plus midazolam (M)
Number of subjects: 21

Group type: COMPARATOR
Intervention: propofol (P)
Number of subjects: 21
Study: 2405741

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion at a dose of 30 ng.kg‐1.min‐1 for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 6994764

Group type: EXPERIMENTAL
Intervention: Guanfacine (0.01 mg/kg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Guanfacine (0.02 mg/kg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Guanfacine (0.04 mg/kg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Guanfacine (0.01, 0.02, 0.04 mg/kg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 6882619

Group type: EXPERIMENTAL
Intervention: Ibopamine 200 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ibopamine 400 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29210932

Group type: EXPERIMENTAL
Intervention: Balance Outcome Measure for Elder Rehabilitation (BOOMER)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Static standing with eyes closed test (component of BOOMER)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Short Physical Performance Battery (SPPB)
Number of subjects: 141
Study: 29351710

Group type: EXPERIMENTAL
Intervention: Internet-based self-help program Deprexis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no access to Deprexis)
Number of subjects: 0
Study: 27454856

Group type: EXPERIMENTAL
Intervention: LCHF (approximately 70% fats)
Number of subjects: 7

Group type: COMPARATOR
Intervention: ICIF (approximately 50% fats)
Number of subjects: 7

Group type: COMPARATOR
Intervention: C (approximately 25% fats)
Number of subjects: 7
Study: 25946916

Group type: EXPERIMENTAL
Intervention: Self-administered acupressure intervention (5 sessions, 3 times a day for 2 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (usual activities)
Number of subjects: 54
Study: 22950651

Group type: EXPERIMENTAL
Intervention: Natural cycle FET (NC-FET)
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Artificial cycle FET (AC-FET)
Number of subjects: 1150
Study: 19891806

Group type: EXPERIMENTAL
Intervention: Active medication
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pill-placebo
Number of subjects: 120
Study: 18798940

Group type: EXPERIMENTAL
Intervention: Computer-aided nursing (CAN) diagnosis system
Number of subjects: 42

Group type: COMPARATOR
Intervention: Handbook of nursing diagnosis
Number of subjects: 42
Study: 15673353

Group type: EXPERIMENTAL
Intervention: Physical activity counseling intervention
Number of subjects: 336

Group type: COMPARATOR
Intervention: Control condition (counseling about tobacco cessation)
Number of subjects: 336
Study: 11831541

Group type: EXPERIMENTAL
Intervention: Fluconazole (100 mg daily for 4 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rectal bromazepam (3 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (control for fluconazole)
Number of subjects: 12
Study: 10348276

Group type: EXPERIMENTAL
Intervention: Radioactive iodine (131I) ablation doses ranging from less than 30 mCi to 100 mCi.
Number of subjects: 0
Study: 8665549

Group type: EXPERIMENTAL
Intervention: Ketamine (mean dose, 58 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alfentanil (mean dose, 11 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2341121

Group type: EXPERIMENTAL
Intervention: Atropine (1 mg intravenously)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cimetropium bromide (5 mg intravenously)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 32
Study: 10248157

Group type: EXPERIMENTAL
Intervention: Intensive health behavior program for obese children
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Smoking prevention program
Number of subjects: 1252

Group type: COMPARATOR
Intervention: General health education program
Number of subjects: 1252
Study: 31571633

Group type: EXPERIMENTAL
Intervention: RISUG (120 μl as bilateral vas intraluminal injection)
Number of subjects: 139
Study: 28327167

Group type: EXPERIMENTAL
Intervention: 3-hour clamp (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 4-hour clamp (Group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional negative drainage (Group C)
Number of subjects: 120
Study: 26573144

Group type: EXPERIMENTAL
Intervention: kContact intervention
Number of subjects: 0
Study: 23025248

Group type: EXPERIMENTAL
Intervention: Living in the Face of Trauma (LIFT) intervention
Number of subjects: 247
Study: 21980445

Group type: EXPERIMENTAL
Intervention: Vi-CRM₁₉₇ vaccine (25.0 µg of Vi antigen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vi-CRM₁₉₇ vaccine (1.25 µg, 5.0 µg, and 12.5 µg of Vi antigen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Licensed polysaccharide vaccine (25.0 µg of Vi antigen)
Number of subjects: 0
Study: 18277222

Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy skills training group (16 sessions, once-weekly)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Wait-list condition
Number of subjects: 24
Study: 17135639

Group type: EXPERIMENTAL
Intervention: Docetaxel plus cyclophosphamide (TC) (75 and 600 mg/m2, respectively; n = 506)
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Doxorubicin plus cyclophosphamide (AC) (60 and 600 mg/m2, respectively; n = 510)
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Docetaxel plus cyclophosphamide (TC)
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Doxorubicin plus cyclophosphamide (AC)
Number of subjects: 1016
Study: 14511925

Group type: EXPERIMENTAL
Intervention: Six fractions per week
Number of subjects: 1476

Group type: COMPARATOR
Intervention: Five fractions per week
Number of subjects: 1476
Study: 11104591

Group type: EXPERIMENTAL
Intervention: Enriched diet (enteral diet supplemented with arginine)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous control diet
Number of subjects: 44